Todd Watanabe, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 75,000 shares at $20.04 ($1.5M) on 2025-10-02, disclosed to the SEC on 2025-10-03.
Scheduled sale ($1.5M) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.91 | 15,000 | $284K | 19.1% |
| 2 | $20.02 | 9,261 | $185K | 12.5% |
| 3 | $20.02 | 9,261 | $185K | 12.5% |
| 4 | $20.04 | 20,739 | $416K | 28.0% |
| 5 | $20.04 | 20,739 | $416K | 28.0% |
| Total | $19.81 avg | 75,000 |
| $1.5M |
| 100% |
| Filing → |
| ARQT | SELL | 2026-03-03 | $1.9M | — | Filing → |
| ARQT | SELL | 2026-02-04 | $506K | — | Filing → |
| ARQT | SELL | 2025-11-24 | $3.0M | — | Filing → |